Comparative Pharmacology
Head-to-head clinical analysis: BETA HC versus BETADERM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BETA HC versus BETADERM.
BETA-HC vs BETADERM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
BETA-HC (hydrocortisone) is a corticosteroid that binds to the glucocorticoid receptor, leading to modulation of gene expression and suppression of inflammatory mediators such as prostaglandins and leukotrienes. It also inhibits phospholipase A2 and reduces cytokine production.
Betamethasone dipropionate is a corticosteroid that exerts anti-inflammatory, antipruritic, and vasoconstrictive effects through induction of phospholipase A2 inhibitory proteins (lipocortins) and inhibition of arachidonic acid release, thereby reducing prostaglandin and leukotriene synthesis.
1-2 tablets (200-400 mg) orally every 6-8 hours as needed for pain; not to exceed 6 tablets (1200 mg) per day.
Topical: Apply a thin film to affected skin twice daily; maximum 100 g per week for adults.
None Documented
None Documented
1.5 hours (beta phase); clinical context: anti-inflammatory effects persist longer than serum levels due to receptor binding and gene transcription
Terminal elimination half-life is approximately 18-36 hours (mean ~24 hours) following topical application; systemic half-life after oral administration is similar, reflecting prolonged tissue retention.
Renal (approximately 75% as metabolites, <5% unchanged); fecal (approximately 15%)
Renal excretion of metabolites (mainly as glucuronide and sulfate conjugates) accounts for approximately 60-70% of elimination; fecal/biliary excretion accounts for 30-40%.
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid